Nuvalent
track record of success resource efficient execution and value creation across an expanding portfolio wholly owned programs loyal emergence from stealth first clinical proof of concept second proof of concept first pivotal study disclosed parallel lead programs initiated two global phase studies demonstrated clinical proof of concept and alk for alk program presented preclinical profiles demonstrated clinical proof of concept initiated phase with supporting desired target product for program registrational intent as disclosed third novel program advanced her program towards listed her paper kim kim mila a with potential to deliver multiple transformative catalysts within cash runway window into i a | Nuvalent
Company
Deck Type
Sector
Industry
Deck date
April 2024
Slide
5 of 42
Similar slides by Nuvalent
See diffirences between slides (animation)
Investor Presentation
February 2024
track record of success resource efficient execution and value creation across an expanding portfolio wholly owned programs my a epee emergence from stealth first clinical proof of concept second proof of concept first pivotal study disclosed parallel lead programs initiated two global phase studies demonstrated clinical proof of concept and alk for alk program presented preclinical profiles demonstrated clinical proof of concept initiated phase with supporting desired target product for program mined ale me disclosed third novel program advanced her program towards listed her ended with approximately in cash cash equivalents and marketable securities unaudited with potential to deliver multiple transformative catalysts within cash runway window into preliminary unaudited estimate only as the date this presentation subject to change following completion year end closing procedures does not present all information necessary for an understanding financial position as a | Nuvalent
Investor Presentation
January 2024
track record of success resource efficient execution and value creation across an expanding portfolio wholly owned programs emergence from first clinical proof of concept second proof of concept first pivotal study disclosed parallel lead programs initiated two global phase studies demonstrated clinical proof of concept and alk for alk program presented preclinical profiles demonstrated clinical proof of concept initiated phase with supporting desired target product for program registrational intent disclosed third novel program advanced her program towards listed her ended with approximately in cash cash equivalents and marketable securities unaudited with potential to deliver multiple transformative catalysts within cash runway window into preliminary unaudited estimate only as the date this presentation subject to change following completion year end closing procedures does not present all information necessary for an understanding financial position as a | Nuvalent
Investor Presentation
January 2024
track record of success resource efficient execution and value creation across an expanding portfolio wholly owned programs emergence from first clinical proof of concept second proof of concept first pivotal study disclosed parallel lead programs initiated two global phase studies demonstrated clinical proof of concept and alk for alk program presented preclinical profiles demonstrated clinical proof of concept initiated phase with supporting desired target product for program registrational intent disclosed third novel program advanced her program towards listed her ended with approximately in cash cash equivalents and marketable securities unaudited with potential to deliver multiple transformative catalysts within cash runway window into preliminary unaudited estimate only as the date this presentation subject to change following completion year end closing procedures does not present all information necessary for an understanding financial position as a | Nuvalent
Related slides by other companies
Equillium
Investor Presentation
August 2023
milestones | Equillium
Calliditas Therapeutics
IPO
June 2020
ongoing pivotal phase clinical trial designed to confirm phase results | Calliditas Therapeutics
Equillium
Investor Presentation
February 2024
milestones | Equillium
Dare Bioscience
Investor Presentation
August 2023
advancing products women want the portfolio snapshot | Dare Bioscience
Other recent decks by Nuvalent
See all presentations (10 decks)
Investor Presentation
February 2024
Investor Presentation
January 2024
Investor Presentation
January 2024
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io